Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cernilton for benign prostatic hyperplasia.

T Wilt1, R Mac Donald, A Ishani

  • 1General Internal Medicine, Department of Veterans Affairs Coordinating Center of the, One Veterans Drive, Minneapolis, Minnesota 55417, USA. wilt.timothy@minneapolis.va.gov

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fourier-transform-spectroscopic photoabsorption cross sections and oscillator strengths for the S<sub>2</sub> BΣu-3-XΣg-3 system.

The Journal of chemical physics·2018
Same author

Predissociation of the B Σu-3 state of S<sub>2</sub>: A coupled-channel model.

The Journal of chemical physics·2018
Same author

Observation of a new electronic state of CO perturbing W ¹Π(v=1).

The Journal of chemical physics·2014
Same author

Orientation of the porphyrin ring in artificial chlorophyll membranes.

The Journal of membrane biology·2013
Same author

The transport of potassium through lipid bilayer membranes by the neutral carriers valinomycin and monactin : Experimental studies to a previously proposed model.

The Journal of membrane biology·2013
Same author

Measurement of a stranger's influence on the behaviour of young children with their mothers.

Journal of child psychology and psychiatry, and allied disciplines·2013
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Cernilton, derived from rye-grass pollen, modestly improves urinary symptoms and nocturia in men with benign prostatic hyperplasia (BPH). Further research is needed to confirm long-term effectiveness and safety.

Area of Science:

  • Urology
  • Phytotherapy
  • Evidence-based medicine

Background:

  • Benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms (LUTS).
  • Phytotherapy is increasingly used for BPH symptom management.
  • Cernilton, from rye-grass pollen, is a phytotherapeutic option for BPH.

Purpose of the Study:

  • To systematically review the effects of Cernilton on urinary symptoms and flow in men with BPH.
  • To assess Cernilton's efficacy compared to placebo and other BPH treatments.

Main Methods:

  • Systematic review of randomized controlled trials and controlled clinical trials.
  • Searched multiple databases (MEDLINE, EMBASE, Cochrane) and contacted manufacturers.
  • Extracted data on patient characteristics, interventions, and outcomes, focusing on urologic symptom scales and urodynamic measures.

Related Experiment Videos

Main Results:

  • Cernilton improved self-rated urinary symptoms versus placebo (RR 2.40) and Tadenan (RR 1.42).
  • Cernilton reduced nocturia compared to placebo (RR 2.05) and Paraprost (WMD -0.40).
  • No significant improvements in urinary flow rates, residual volume, or prostate size were observed. Adverse events were rare.

Conclusions:

  • Available evidence suggests Cernilton is well-tolerated and offers modest improvement in urologic symptoms, including nocturia.
  • Study limitations include short duration, small sample sizes, and potential quality issues.
  • Further high-quality, long-term randomized controlled trials are necessary to validate Cernilton's clinical effectiveness and safety.